Search - tctmd.com

Displaying 1 - 20 of 311

Sort: Relevancy | Date

News Daily News

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Michael O'Riordan

January 08, 2026

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Daily News

Revascularization Decisions in the Elderly Require a Holistic Approach: AHA

Caitlin E. Cox

November 24, 2025

News Daily News

For Monotherapy, P2Y12 Inhibitor Bests Aspirin After PCI for ACS: Meta-analysis

Yael L. Maxwell

August 14, 2025

News Daily News

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

Todd Neale

July 24, 2025

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

News Daily News

Trade-offs With Invasive Strategy in Older Patients With ACS: Meta-analysis

Michael O'Riordan

July 03, 2025

News Daily News

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

Yael L. Maxwell

June 09, 2025

News Daily News

JACC Dedicates Issue to Deep Dive on Latest ACS Guidelines

Todd Neale

June 06, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Daily News

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Michael O'Riordan

March 26, 2025

News Daily News

ACC Releases ‘Concise Clinical Guidance’ for Cardiogenic Shock Care

Caitlin E. Cox

March 19, 2025

News Daily News

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Michael O'Riordan

March 11, 2025

News Daily News

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Michael O'Riordan

March 06, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Daily News

Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments

Michael O'Riordan

January 03, 2025

News Daily News

BMJ Investigation Revives Questions About PLATO, Ticagrelor

Todd Neale

December 20, 2024

Advertisement

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Year in Review: Top Prevention Stories of 2025

Revascularization Decisions in the Elderly Require a Holistic Approach: AHA

For Monotherapy, P2Y12 Inhibitor Bests Aspirin After PCI for ACS: Meta-analysis

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Trade-offs With Invasive Strategy in Older Patients With ACS: Meta-analysis

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

JACC Dedicates Issue to Deep Dive on Latest ACS Guidelines

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

ACC Releases ‘Concise Clinical Guidance’ for Cardiogenic Shock Care

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments

BMJ Investigation Revives Questions About PLATO, Ticagrelor

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content